DYAI vs. CSBR, BCLI, LOGC, OTLK, ZURA, IPHA, ELEV, IVVD, CHRS, and GLUE
Should you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Champions Oncology (CSBR), Brainstorm Cell Therapeutics (BCLI), LogicBio Therapeutics (LOGC), Outlook Therapeutics (OTLK), Zura Bio (ZURA), Innate Pharma (IPHA), Elevation Oncology (ELEV), Invivyd (IVVD), Coherus BioSciences (CHRS), and Monte Rosa Therapeutics (GLUE).
Dyadic International (NASDAQ:DYAI) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, community ranking, dividends, valuation and analyst recommendations.
Dyadic International received 9 more outperform votes than Champions Oncology when rated by MarketBeat users. Likewise, 63.97% of users gave Dyadic International an outperform vote while only 60.08% of users gave Champions Oncology an outperform vote.
Dyadic International currently has a consensus price target of $6.00, indicating a potential upside of 175.23%. Champions Oncology has a consensus price target of $7.50, indicating a potential upside of 65.56%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts clearly believe Dyadic International is more favorable than Champions Oncology.
28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 28.8% of Dyadic International shares are owned by company insiders. Comparatively, 45.7% of Champions Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Champions Oncology has higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Champions Oncology, indicating that it is currently the more affordable of the two stocks.
Champions Oncology has a net margin of -19.76% compared to Dyadic International's net margin of -347.92%. Dyadic International's return on equity of -116.14% beat Champions Oncology's return on equity.
In the previous week, Champions Oncology had 25 more articles in the media than Dyadic International. MarketBeat recorded 28 mentions for Champions Oncology and 3 mentions for Dyadic International. Champions Oncology's average media sentiment score of 1.04 beat Dyadic International's score of 0.95 indicating that Champions Oncology is being referred to more favorably in the news media.
Dyadic International has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.
Summary
Champions Oncology beats Dyadic International on 9 of the 17 factors compared between the two stocks.
Get Dyadic International News Delivered to You Automatically
Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dyadic International Competitors List
Related Companies and Tools
